Long-Term Results of Blood and Marrow Transplantation for Hodgkin’s Lymphoma
Görgün Akpek(Banner MD Anderson Cancer Center), Richard J. Jones(Sidney Kimmel Comprehensive Cancer Center), Stephen J. Noga, Donald J. Fuller(Johns Hopkins University), Paul V. O’Donnell(Johns Hopkins Hospital), Marianna Zahurak(Bloomberg (United States)), Ephraim J. Fuchs(Johns Hopkins University), Richard F. Ambinder(Johns Hopkins University), Robert A. Brodsky(Johns Hopkins University), Steven Piantadosi(Brigham and Women's Hospital), Risa B. Mann(Boston University), Carole B. Miller(Saint Agnes Hospital), Georgia B. Vogelsang(Johns Hopkins University), Ian W. Flinn(Tennessee Oncology), E Seifter, Ross A. Abrams(Rush University Medical Center)
Cited by 163
Related Papers
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
|New England Journal of Medicine|2017|6k
National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group Report
|Biology of Blood and Marrow Transplantation|2014|5.4k
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial
|The Lancet Oncology|2018|2.3k
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2013|2.2k
Neoadjuvant PD-1 Blockade in Resectable Lung Cancer
|New England Journal of Medicine|2018|2.1k